Somatostatin for Uveitic Cystoid Macular Edema (CME).
OBJECTIVE
To report the favorable response of bilateral recalcitrant uveitic cystoid macular edema (CME) to treatment with a somatostatin analog.


METHODS
Medical ophthalmic history and the results of ophthalmic examinations were recorded. Fluorescein angiography (FA) studies were reviewed.


RESULTS
A 52-year-old white female with intermediate uveitis developed bilateral recalcitrant CME. Treatment with subcutaneous injections of the somatostatin analog octreotide resulted in partial resolution of the CME and improvement of visual acuity.


CONCLUSIONS
Somatostatin may play a role in the treatment of CME secondary to uveitis.
Papadaki
Thekla
T
Ocular Immunology and Uveitis Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
Zacharopoulos
Ioannis
I
Iaccheri
Barbara
B
Fiore
Tito
T
Foster
C Stephen
CS
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007279:Injections, Subcutaneous; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives*; D015867:Uveitis, Intermediate / Q000150:complications*
D018931:Antineoplastic Agents, Hormonal; D013004:Somatostatin; D015282:Octreotide